Expansion of antibody scaffold diversity has the potential to expand the neutralizing capacity of the immune system and to generate enhanced therapeutics and probes. Systematic exploration of scaffold diversity could be facilitated with a modular and chemical scaffold for assembling proteins, such as DNA. However, such efforts require simple, modular, and site-specific methods for coupling antibody fragments or bioactive proteins to nucleic acids. To address this need, we report a modular approach for conjugating synthetic oligonucleotides to proteins with aldehyde tags at either terminus or internal loops. The resulting conjugates are assembled onto DNA-based scaffolds with low nanometer spatial resolution and can bind to live cells. Thus, this modular and site-specific conjugation strategy provides a new tool for exploring the potential of expanded scaffold diversity in immunoglobulin-based probes and therapeutics.
Expansion of antibody scaffold diversity has the potential to expand the neutralizing capacity of the immune system and to generate enhanced therapeutics and probes. Systematic exploration of scaffold diversity could be facilitated with a modular and chemical scaffold for assembling proteins, such as DNA. However, such efforts require simple, modular, and site-specific methods for coupling antibody fragments or bioactive proteins to nucleic acids. To address this need, we report a modular approach for conjugating synthetic oligonucleotides to proteins with aldehyde tags at either terminus or internal loops. The resulting conjugates are assembled onto DNA-based scaffolds with low nanometer spatial resolution and can bind to live cells. Thus, this modular and site-specific conjugation strategy provides a new tool for exploring the potential of expanded scaffold diversity in immunoglobulin-based probes and therapeutics.
DNA–protein conjugates
can be assembled into nanoscale objects through the power of structural
DNA nanotechnology. These motifs have the potential to revolutionize
a number of biological and biomedical applications.[1−3] One particular
application of interest is antibody engineering using DNA scaffolds.[4]In vivo, antibodies of different
classes have different biological activities and serve specialized
roles during the immune response. An antibody’s class is determined
by its constant region, or scaffold, which encodes the valency, effector
functions, and higher-order architecture of the pendant variable domains.
Expanding scaffold diversity in the antibody repertoire has the potential
to expand the neutralizing capacity of the immune system, i.e. by
delivering new effectors, increasing avidity, or modulating specificity.
However, systematic exploration of antibody scaffold geometry, valency,
and combinatorial binding capacity is difficult with protein-based
scaffolds due to the challenges associated with protein design.[5−7] DNA-based scaffolds, in contrast, are programmable and can combinatorially
control the position and orientation of pendant proteins with nanometer
resolution (Scheme 1A). Appropriately designed
DNA scaffolds could assemble proteins that recognize specific combinations
of receptors on cell surfaces,[4] and even
deliver protein-based therapeutics specifically to these cells.[8,9]
Scheme 1
Modular strategies for controlling antibody scaffold geometry
using DNA–conjugates of aldehyde-tagged proteins. (A)
(i) At least three unique functions can be incorporated on a Y-type
(e.g. IgG) antibody scaffold. (ii) Protein–DNA conjugates can
be used to selectively assemble Fab-bearing trimers. (iii) The DNA
may be used as a handle for assembly of more complex scaffold architectures.
(B) Attachment of oligonucleotides to aldehyde tags at protein termini
or internal loops may proceed through at least four strategies: direct
conjugation to DMT-protected aminooxy-modified DNA 1 or
HIPS-modified DNA 2; or indirect conjugation through
bifunctional polyethylene glycol 3 and subsequent copper-catalyzed
triazole formation with hexynyl-modified DNA 4, or copper-free
triazole formation to DBCO-modified DNA 5
To fully realize the potential of using DNA
scaffolds to expand
the repertoire of antibody structure and function, more modular strategies
for preparing DNA–protein conjugates are required. Ideal strategies
would provide modularity in linkage chemistries, linkage site (e.g.,
termini or internal loops), and expression host. Aldehyde tagged proteins
satisfy these requirements (Scheme 1B). Among
peptide tags and self-ligating proteins,[10−18] the aldehyde tag uniquely combines the advantages of a short consensus
sequence (5 amino acids), a bioorthogonal handle which is amenable
to conjugation through a number of chemical linkers, diverse prokaryotic
or eukaryotic expression hosts, and compatibility with insertion at
any position in a protein’s primary sequence.[19−22]We explored the potential of aldehyde tagged proteins to form
defined
DNA–protein conjugates using a model substrate (maltose binding
protein, MBP) bearing a C-terminal aldehyde tag expressed in E. coli. Coexpression of Formylglycine Generating Enzyme
(FGE) leads to the post-translational conversion of the cysteine in
the aldehyde tag consensus sequence (CxPxR) to formylglycine (Scheme S1). We also synthesized an oligonucleotide
functionalized with a 5′-dimethoxytrityl (DMT)-protected
aminooxy nucleophile, 1, from commercially available
reagents. DMT-protection of the alkoxyamine stabilizes the product
for storage but is rapidly deprotected in situ under
the mildly acidic conjugation conditions. The resulting oxime product
is observed as a higher molecular weight species by gel electrophoresis,
and densitometry of the banding pattern indicated an 81% yield with
respect to protein concentration (Figure 1A,
lane 2). No conjugate was formed using a C → A mutation in
the aldehyde tag consensus sequence (Figure S1). Thus, direct conjugation of aminooxy-modified DNA 1 to aldehyde-tagged proteins generates product efficiently using
only commercially available reagents.
Figure 1
Modular and site-specific conjugation
of oligonucleotides
to aldehyde-tagged proteins. (A) SDS-PAGE analysis of crude
reactions between aldehyde-tagged Maltose Binding Protein (MBP) and
the indicated functionalized oligonucleotide (Scheme 1B). (B) MBP–DNA conjugates after purification by anion
exchange chromatography. (C) MBP–DNA conjugates incubated with
complementary and noncomplementary FITC–DNA and analyzed by
SDS-PAGE.
Modular and site-specific conjugation
of oligonucleotides
to aldehyde-tagged proteins. (A) SDS-PAGE analysis of crude
reactions between aldehyde-tagged Maltose Binding Protein (MBP) and
the indicated functionalized oligonucleotide (Scheme 1B). (B) MBP–DNA conjugates after purification by anion
exchange chromatography. (C) MBP–DNA conjugates incubated with
complementary and noncomplementary FITC–DNA and analyzed by
SDS-PAGE.Like other bioconjugation techniques
such as thiol-maleimide coupling,[23,24] the oxime
linkage formed between 1 and an aldehyde-tagged
protein is hydrolytically unstable upon long-term incubation in serum.
This observation motivated the development of alternate conjugation
strategies such as the Hydrazino-iso-Pictet–Spengler (HIPS)
ligation.[25] This recently reported reaction
proceeds efficiently at near-physiological pH to form a stable covalent
linkage with aldehyde tagged proteins. We therefore coupled the HIPS
reagent to a 5′ amino-modified oligonucleotide and incubated
the product 2 with aldehyde-tagged MBP at pH 5.5 to generate
a DNA–protein conjugate in 62% yield (Figure 1A, lane 3). While the HIPS reagent must be synthesized prior
to DNA conjugation, HIPS ligation proceeds at higher pH and forms
a covalent and an irreversible C–C bond between DNA and protein.[26]Additionally, we explored the potential
to convert the formylglycine
to a more reactive functionality for cases where more rapid coupling
is required. Aldehyde bearing MBP was treated with an excess of a
low molecular weight bifunctional linker 3 to introduce
an azide group. Excess linker drives this reaction to completion and
is easily removed by gel filtration due to its low molecular weight.
Subsequent coupling with alkyne-modified DNA 4 occurred
upon incubation with biocompatible copper stabilizing ligands such
as BTTP,[27] copper(II) sulfate, and sodium
ascorbate with yields between 63% and 87% (Figure 1A, lane 4). Alkyne-modified DNA is inexpensive to synthesize
in large quantities, allowing reaction scale-up and purification of
the conjugate by anion exchange chromatography (Figures 1B, S2). The functionality and addressability
of the DNA on the conjugate was verified by hybridizing it with a
matching fluorescein isothiocyanate (FITC)-conjugated oligo (Figure 1C).Conjugation of the azide-bearing protein
with DNA can also proceed
efficiently under copper-free conditions with dibenzocyclooctyne (DBCO)-modified
DNA, 5. Incubation of azide-bearing MBP with 5 generated product in 79% yield with respect to protein (Figure S3). Together, this combination of four
conjugation strategies provides flexible means of converting aldehyde-tagged
proteins into DNA–protein conjugates with diverse physicochemical
properties.A key advantage of small peptides such as the aldehyde
tag is that
they can be used to prepare DNA–protein conjugates at either
terminus or internal loops of immunoglobulins. For example, we inserted
an aldehyde tag onto the C-terminus of a Fab raised against the Urokinase
Plasminogen Activator Receptor (uPAR), an extracellular scaffold protein
that regulates cell migration and invasion.[28,29] After conversion of the formylglycine to an azide using the bifunctional
linker 3, the product was conjugated to 4 using BTTP-stabilized click chemistry (Figure 2A). The resulting DNA–protein conjugate retained its ability
to specifically bind uPAR on live cells. For example, an anti-uPARFab–DNA conjugate hybridized with a FITC-labeled oligonucleotide
was able to efficiently label uPAR-expressing H1299 cells (Figure S4).
Figure 2
DNA conjugation to aldehyde-tagged
immunogloblulins at either
terminus or an internal loop. (A) SDS-PAGE analysis of DNA
conjugated to the N-terminus of uPAR-binding Fab expressed in E. coli and then treated in vitro with
FGE. Compounds 3 and then 4 were used to
label the Fab with DNA. (B) DNA-conjugated to C-or N-terminal labeled
Fc fragments expressed in FGE-expressing CHO cells using 3 and then 4. (C) DNA-conjugated to an internally labeled
IgG expressed in FGE-expressing CHO cells using 1.
DNA conjugation to aldehyde-tagged
immunogloblulins at either
terminus or an internal loop. (A) SDS-PAGE analysis of DNA
conjugated to the N-terminus of uPAR-binding Fab expressed in E. coli and then treated in vitro with
FGE. Compounds 3 and then 4 were used to
label the Fab with DNA. (B) DNA-conjugated to C-or N-terminal labeled
Fc fragments expressed in FGE-expressing CHO cells using 3 and then 4. (C) DNA-conjugated to an internally labeled
IgG expressed in FGE-expressing CHO cells using 1.We also prepared glycosylated
Fc fragments of a human IgG with
the aldehyde tag inserted at the N- or C-terminus. Coexpression of
these proteins with FGE in CHO cells yielded aldehyde-tagged protein
with moderate levels of conversion. Transformation of the formylglycine
to an alkyne using 3 and BTTP-stabilized click ligation
to alkyne-modified oligonucleotides 4 generated a higher
molecular weight species, consistent with formation of DNA–protein
conjugates (Figure 2B). The lower yield of
product observed for the C-terminally labeled site suggests that aldehyde
reactivity depends on its placement within the primary sequence of
the protein. Finally, we expressed a fully glycosylated IgG containing
an aldehyde tag on an internal loop in FGE-expressing CHO cells. Incubation
of different concentrations of aminooxy-modified DNA 1 with the IgG resulted in the appearance of a higher molecular weight
band on a reducing SDS-PAGE gel that is consistent with a DNA-conjugated
light chain (Figure 2C). Together, these experiments
indicate the necessary modularity of tag placement and expression
hosts when preparing DNA–protein conjugates for assembly into
nanoscale geometries on DNA-scaffolds.As our goal of synthesizing
DNA–protein conjugates is to
facilitate the assembly of proteins into antibody-like geometries,
we explored the efficiency with which several simple DNA motifs mimicking
the geometry of antibody scaffolds could be prepared from these reagents.
We conjugated aldehyde-tagged MBP to 20 and 26 base oligonucleotides
designed to self-assemble into dimers and trimers, respectively (Figure 3A). After hybridizing in PBS for 1 h at 25 °C,
SDS-PAGE analysis indicated that both dimers and trimers assembled
efficiently (Figure 3B).
Figure 3
Modular assembly
of protein-bearing DNA multimers and their
interactions with live cells. (A) Assembly of protein–DNA
conjugates into dimers and trimers based on oligonucleotide sequence.
(B) SDS-PAGE of DNA-linked monomer (i), along with crude dimer (ii)
and trimer (iii) assemblies. (C) Flow cytometry analysis of uPAR-expressing
H1299 carcinoma cells incubated with DNA-scaffolded trimer bearing
Fab and Alexa488-labeled MBP. (D) A field of negative-stained DNA-scaffolded
MBP trimers imaged by transmission electron microscopy. (E) Fab–MBP–MBP
trimers. The red arrow points to the Fab of the heterotrimeric construct.
(F) SDS-PAGE of (1) MBP–DNA conjugate, (2) Fab–DNA conjugate,
(3) a Fab and MBP bearing heterodimer, and (4) a Fab and MBP bearing
heterotetramer using scaffolding strands with a variable length of
X base pairs (here, x=16).
Modular assembly
of protein-bearing DNA multimers and their
interactions with live cells. (A) Assembly of protein–DNA
conjugates into dimers and trimers based on oligonucleotide sequence.
(B) SDS-PAGE of DNA-linked monomer (i), along with crude dimer (ii)
and trimer (iii) assemblies. (C) Flow cytometry analysis of uPAR-expressing
H1299 carcinoma cells incubated with DNA-scaffolded trimer bearing
Fab and Alexa488-labeled MBP. (D) A field of negative-stained DNA-scaffolded
MBP trimers imaged by transmission electron microscopy. (E) Fab–MBP–MBP
trimers. The red arrow points to the Fab of the heterotrimeric construct.
(F) SDS-PAGE of (1) MBP–DNA conjugate, (2) Fab–DNA conjugate,
(3) a Fab and MBP bearing heterodimer, and (4) a Fab and MBP bearing
heterotetramer using scaffolding strands with a variable length of
X base pairs (here, x=16).Additionally, DNA–protein conjugates assembled into
small
multiprotein motifs interacted efficiently with cell surfaces. For
example, we used flow cytometry to analyze whether MBP/Fab heterotrimers
retained their ability to interact with cells expressing uPAR. As
a reporter for cell binding, we prepared an MBP–DNA conjugate
modified with AlexaFluor-488 and assembled the resulting fluorescent
MBP(488)–DNA conjugates with Fab–DNA to form heterotrimers.
Incubation of the uPAR-expressing lung carcinoma cell line H1299 with
the Fab-containing heterotrimer resulted in an increase in mean fluorescence
in comparison to unlabeled cells (Figure 3C).
To confirm that the heterotrimers were interacting specifically with
uPAR, we preincubated the H1299 cells with nonfluorescent monomeric
anti-uPARFab prior to addition of the Fab-MBP(488)-MBP(488) trimer
and saw no increase in fluorescence. Similarly, fluorescence of HumanEmbryonic Kidney (HEK) cells, which do not express uPAR, was unchanged
after incubation with the protein heterotrimer (Figure S5).We examined the spatial organization of
DNA-scaffolded proteins
by negative stain transmission electron microscopy. Individual molecules
of MBP in protein trimers were easily identifiable as light spots
with a dark halo on a salt-and-pepper background (Figure 3D). In contrast to MBP, antibody fragments have
more distinct features that can be identified as one of two distinct
shapes (Figure S6). Thus, in heterotrimers,
a single Fab protein was identifiable alongside an MBP dimer (Figure 3E). We calculated the distance between the center
of individual proteins and the trimer centroid as 8.12 nm and measured
an average spacing of 7.03 nm ±1.5 nm (s.d.) consistent with
our estimate (Figure S7). The relatively
large standard deviation in our measurements may indicate some conformational
flexibility of the DNA scaffold. Additional spatial control and rigidity
might be achieved using DNA motifs with longer persistence lengths,
such as the double crossover motif.[30,31] Moreover,
the ability to modularly insert rigid or shorter chemical linkers
would provide additional spatial control in these nanostructures.Finally, because scaffold valency plays a central role in the immune
system (IgG vs IgA vs IgM), we explored the hierarchical assembly
of simple trimer motifs into higher-order structures. For example,
we used an unmodified oligonucleotide as one arm of the trimer motif
to assemble MBP–Fab dimers into tetramers, where the distance
between each dimer could be varied based on the length of the unmodified
scaffold DNA strands (Figure 3F). Elaboration
of this simple strategy would allow for the assembly of scaffold protein
assemblies of considerably higher valency and complexity.In
conclusion, we describe a simple and modular method for conjugating
and then assembling multiple proteins onto DNA scaffolds. Our approach
utilizes the aldehyde tag, which is genetically incorporated into
the primary sequence of proteins expressed in both bacterial and mammalian
expression systems. We tested four bioconjugation reactions that generate
site-specific DNA–protein conjugates in moderate to excellent
yield. The variety of strategies for conjugation of DNA to aldehyde-tagged
proteins provides flexibility in linker chemistry and geometry, and
is accessible to individuals with varying levels of synthetic expertise.
Moreover, the ability to insert the aldehyde tag at both protein termini
or in an internal loop will provide the potential for orientational
control of proteins on DNA scaffolds. DNA–protein conjugates
can be modularly assembled into dimeric and trimeric nanostructures
resembling antibody scaffolds and interfaced with living cells. Transmission
electron microscopy verified that the DNA scaffolds arranged proteins
as predicted. These motifs can also be assembled hierarchically into
structures of greater complexity. We anticipate expanding our DNA
scaffold libraries to generate large collections of macromolecular
assemblies varying in valency and architecture that may have novel
activities as nanoscale probes or antibodies with unique specificities
and biological activities.
Authors: Sai Duriseti; David H Goetz; Daniel R Hostetter; Aaron M LeBeau; Ying Wei; Charles S Craik Journal: J Biol Chem Date: 2010-05-25 Impact factor: 5.157
Authors: Peng Wu; Wenqing Shui; Brian L Carlson; Nancy Hu; David Rabuka; Julia Lee; Carolyn R Bertozzi Journal: Proc Natl Acad Sci U S A Date: 2009-02-06 Impact factor: 11.205
Authors: Georgyi V Los; Lance P Encell; Mark G McDougall; Danette D Hartzell; Natasha Karassina; Chad Zimprich; Monika G Wood; Randy Learish; Rachel Friedman Ohana; Marjeta Urh; Dan Simpson; Jacqui Mendez; Kris Zimmerman; Paul Otto; Gediminas Vidugiris; Ji Zhu; Aldis Darzins; Dieter H Klaubert; Robert F Bulleit; Keith V Wood Journal: ACS Chem Biol Date: 2008-06-20 Impact factor: 5.100
Authors: Xiaoyu Zhang; Zihan Xu; Dina S Moumin; Daniel A Ciulla; Timothy S Owen; Rebecca A Mancusi; José-Luis Giner; Chunyu Wang; Brian P Callahan Journal: Bioconjug Chem Date: 2019-10-10 Impact factor: 4.774
Authors: Natalie M Rachel; Daniela Quaglia; Éric Lévesque; André B Charette; Joelle N Pelletier Journal: Protein Sci Date: 2017-11 Impact factor: 6.725
Authors: Dona York; Jeanne Baker; Patrick G Holder; Lesley C Jones; Penelope M Drake; Robyn M Barfield; Gregory T Bleck; David Rabuka Journal: BMC Biotechnol Date: 2016-02-24 Impact factor: 2.563
Authors: Efrat T Harel; Penelope M Drake; Robyn M Barfield; Irene Lui; Shauna Farr-Jones; Laura Van't Veer; Zev J Gartner; Evan M Green; André Luiz Lourenço; Yifan Cheng; Byron C Hann; David Rabuka; Charles S Craik Journal: Antibodies (Basel) Date: 2019-11-05
Authors: Kurt Housh; Jay S Jha; Tuhin Haldar; Saosan Binth Md Amin; Tanhaul Islam; Amanda Wallace; Anuoluwapo Gomina; Xu Guo; Christopher Nel; Jesse W Wyatt; Kent S Gates Journal: DNA Repair (Amst) Date: 2020-12-24
Authors: Chenguang Lou; Manuel C Martos-Maldonado; Charlotte S Madsen; Rasmus P Thomsen; Søren Roi Midtgaard; Niels Johan Christensen; Jørgen Kjems; Peter W Thulstrup; Jesper Wengel; Knud J Jensen Journal: Nat Commun Date: 2016-07-28 Impact factor: 14.919
Authors: Betty C B Huang; Yun Cheol Kim; Stefanie Bañas; Robyn M Barfield; Penelope M Drake; Igor Rupniewski; William E Haskins; David Rabuka Journal: MAbs Date: 2018-09-25 Impact factor: 5.857